𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase II trial of topotecan in patients with advanced renal cell carcinoma

✍ Scribed by Teresa Murray Law; David H. Ilson; Robert J. Motzer

Publisher
Springer US
Year
1994
Tongue
English
Weight
159 KB
Volume
12
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of Didemnin B in patients
Phase II trial of Didemnin B in patients with advanced renal cell carcinoma
✍ Robert Motzer; Howard Scher; Dean Bajorin; Cora Sternberg; George J. Bosl πŸ“‚ Article πŸ“… 1990 πŸ› Springer US 🌐 English βš– 115 KB

Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5070) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell

A Phase II trial of topotecan and gemcit
A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma
✍ David A. Rinaldi; Nancy A. Lormand; Joseph E. Brierre; James L. Cole; Brian C. B πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 62 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Multiple trials have been performed to evaluate second‐line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; FrΓ©dΓ©ric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 71 KB πŸ‘ 3 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p